Trastuzumab Deruxtecan

T-DXd Combinations Redefine Therapeutic Boundaries in HER2-Low Metastatic Breast Cancer: Key Findings from DESTINY-Breast08

By MedXY 01/13/2026

The DESTINY-Breast08 phase 1b study demonstrates that trastuzumab deruxtecan (T-DXd) combined with chemotherapy, AKT inhibitors, or endocrine therapy is manageable and clinically active in HER2-low metastatic breast cancer, offering new pathways for treatment intensification.

Clinical Updates news Oncology

Trastuzumab Deruxtecan in HER2-Overexpressing NSCLC: Efficacy, Safety, and the Challenges of Combination Therapy in DESTINY-Lung03

By MedXY 01/08/2026

This review analyzes the Phase 1b DESTINY-Lung03 trial results, highlighting the robust efficacy of trastuzumab deruxtecan monotherapy in HER2-overexpressing NSCLC and the prohibitive toxicity encountered when combined with durvalumab and platinum-based chemotherapy.

news Oncology

Trastuzumab Deruxtecan Redefines Postneoadjuvant Care for High-Risk HER2-Positive Early Breast Cancer: Insights from DESTINY-Breast05

By MedXY 12/18/2025

The DESTINY-Breast05 trial demonstrates that Trastuzumab Deruxtecan significantly improves invasive disease-free survival compared to Trastuzumab Emtansine in patients with residual HER2-positive early breast cancer, establishing a new potential standard of care while highlighting the need for vigilant monitoring of interstitial lung disease.

news Oncology

Trastuzumab Deruxtecan plus Pertuzumab Becomes First-Line Standard for HER2‑Positive Metastatic Breast Cancer: Clinical Implications of the DESTINY‑Breast09 Approval

By MedXY 12/16/2025

The FDA has approved trastuzumab deruxtecan with pertuzumab as first-line therapy for unresectable or metastatic HER2‑positive breast cancer after DESTINY‑Breast09 showed a large PFS benefit versus standard THP; safety and maintenance strategy questions remain.

Hematology-Oncology news Oncology

DESTINY-Breast04 Consolidated: Trastuzumab Deruxtecan Improves Survival and Maintains Quality of Life in HER2‑Low Metastatic Breast Cancer

By MedXY 11/12/2025

DESTINY‑Breast04 shows trastuzumab deruxtecan (T‑DXd) significantly improves progression‑free and overall survival vs physician’s choice chemotherapy in HER2‑low metastatic breast cancer, with manageable safety and preserved patient‑reported quality of life.

news OB/GYN & Women's Health Oncology

Trastuzumab Deruxtecan Plus Pertuzumab: A Promising First-Line Therapy for HER2-Positive Metastatic Breast Cancer

By MedXY 10/31/2025

Trastuzumab deruxtecan combined with pertuzumab significantly improves progression-free survival over standard therapy in first-line HER2-positive metastatic breast cancer, offering enhanced response duration with manageable safety.

Internal Medicine Oncology Specialties

Real-World Insights into HER2-Positive Metastatic Breast Cancer Treatments: Comparing T-DXd, T-DM1, and Tucatinib

By MedXY 10/18/2025

This study uses real-world data to compare the effectiveness and safety of trastuzumab deruxtecan versus trastuzumab emtansine and tucatinib in HER2-positive metastatic breast cancer, confirming their clinical value.

Oncology Specialties

Enhancing Quality of Life in ERBB2-Positive Metastatic Breast Cancer: The PRO-DUCE Trial on Electronic Symptom and Vital Sign Monitoring During Trastuzumab Deruxtecan Therapy

By MedXY 09/11/2025

The PRO-DUCE randomized trial demonstrates that electronic symptom and vital sign monitoring during trastuzumab deruxtecan therapy can preserve quality of life in ERBB2-positive metastatic breast cancer patients, with notable improvements in functional outcomes and fatigue management.

Clinical Updates news Oncology

FDA Approval of Trastuzumab Deruxtecan: Advancing Treatment for HR-Positive HER2-Low and Ultralow Metastatic Breast Cancer

By MedXY 09/08/2025

Trastuzumab deruxtecan (T-DXd) gains FDA approval for HR-positive, HER2-low and HER2-ultralow unresectable or metastatic breast cancer after endocrine therapy progression, offering significant progression-free survival benefits over chemotherapy.

news Oncology Specialties

Trastuzumab Deruxtecan versus Ramucirumab plus Paclitaxel in HER2-Positive Metastatic Gastric Cancer: Advances from Phase 3 Trials and Real-World Data

By MedXY 07/31/2025

Phase 3 data show trastuzumab deruxtecan significantly improves survival over ramucirumab plus paclitaxel in HER2-positive metastatic gastric cancer, with manageable safety, supported by real-world evidence from Japan.